Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal

被引:7
作者
Saluja, Tarun [1 ]
Giri, Bishnu Rath [2 ]
Chaudhary, Shipra [4 ]
Tamrakar, Dipesh [5 ]
Kanodia, Piush [6 ]
Palkar, Sonali [7 ]
Vemula, Sridhar [1 ]
Chinaworapong, Suchada [1 ]
Kim, Bomi [1 ]
Gupta, Birendra Prasad [1 ]
Kyoung Jo, Sue [1 ]
Aspinall, Sanet [8 ]
Rai, Ganesh Kumar [3 ]
Steele, Duncan [9 ]
Kim, Jerome H. [1 ]
Wartel, T. Anh [1 ]
Sahastrabuddhe, Sushant [1 ]
机构
[1] Int Vaccine Inst, SNU Res Pk, Seoul 08826, South Korea
[2] Kanti Childrens Hosp, Pediat Hematol Oncol Unit, Kathmandu, Nepal
[3] Kanti Childrens Hosp, Kathmandu, Nepal
[4] BP Koirala Inst Hlth Sci, Dharan, Nepal
[5] Kathmandu Univ, Sch Med Sci, Dept Community Med, Dhulikhel, Nepal
[6] Nepalgunj Med Coll, Dept Pediat, Nepalganj, Nepal
[7] Bharti Hosp, Pune, Maharashtra, India
[8] Ardent Consulting Pty Ltd, Pretoria, South Africa
[9] Bill & Melinda Gates Fdn, Enter Vaccines Enter & Diarrhoeal Dis, Global Hlth, Seattle, WA USA
关键词
Capacity building; resource-limited settings; phase III; vaccine trial; clinical trial;
D O I
10.1080/21645515.2020.1855955
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Clinical trials are complicated, time-consuming and costly. From the initial screening, informed consent and recruitment of the participants' to study completion, the sponsor must undertake a wide array of complex and closely monitored operations, complying with international standards for human subject research and local requirements. Conducting these studies in an underdeveloped country, with limited resources, infrastructure, and experience with regulated clinical trials adds to this complexity. The initial site selection, set up and preparatory activities for the clinical trial are crucial to minimizing the risks to both participants and to successful completion during the subsequent study execution. In this paper, we describe the experience and lessons learned of building clinical trial site capacity in terms of infrastructure and human resource development for a Phase III vaccine clinical trial. We believe that sharing the experience of setting up a clinical trial in a resource-limited country will enable other entities contemplating clinical research in these countries, to prepare and plan ahead, to minimize the impact of barriers, and to contribute to bringing more studies to the countries where people live with the burden of vaccine-preventable, poverty-associated diseases.
引用
收藏
页码:2149 / 2157
页数:9
相关论文
共 27 条
[1]   Barriers for conducting clinical trials in developing countries- a systematic review [J].
Alemayehu, Chalachew ;
Mitchell, Geoffrey ;
Nikles, Jane .
INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH, 2018, 17
[2]   The ethics of clinical research in the Third World [J].
Angell, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (12) :847-849
[3]  
[Anonymous], 2015, GLOBALIZATION HEALTH
[4]  
[Anonymous], Safety and immunogenicity Study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 Infection (COVID-19)
[5]  
[Anonymous], Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice
[6]   The burden of typhoid fever in low- and middle-income countries: A meta-regression approach [J].
Antillon, Marina ;
Warren, Joshua L. ;
Crawford, Forrest W. ;
Weinberger, Daniel M. ;
Kurum, Esra ;
Pak, Gi Deok ;
Marks, Florian ;
Pitzer, Virginia E. .
PLOS NEGLECTED TROPICAL DISEASES, 2017, 11 (02)
[7]   Evidence-based global health [J].
Buekens, P ;
Keusch, G ;
Belizan, J ;
Bhutta, ZA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (21) :2639-2641
[8]   Innovation in the pharmaceutical industry: New estimates of R&D costs [J].
DiMasi, Joseph A. ;
Grabowski, Henry G. ;
Hansen, Ronald W. .
JOURNAL OF HEALTH ECONOMICS, 2016, 47 :20-33
[9]   What makes clinical research in developing countries ethical? The benchmarks of ethical research [J].
Emanuel, EJ ;
Wendler, D ;
Killen, J ;
Grady, C .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (05) :930-937
[10]   Clinical trials in the developing world [J].
Epstein, Miran .
LANCET, 2007, 369 (9576) :1859-1859